Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVZO-1418 + combination agent 1 + combination agent 2
- Development stage
- Unknown
- Lead developer
- Avenzo Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AVZO-1418 + combination agent 1 + combination agent 2** is an investigational combination therapy comprising **AVZO-1418**, a bispecific antibody-drug conjugate (ADC) that targets both **EGFR (Epidermal Growth Factor Receptor)** and **HER3 (Human Epidermal Growth Factor Receptor 3)**, plus two additional agents (names not specified). AVZO-1418 leverages a topoisomerase I inhibitor payload and is engineered for high selectivity and internalization in EGFR/HER3 co-expressing tumor cells, potentially overcoming resistance to EGFR TKIs and treating advanced solid tumors including lung, breast, and head and neck cancers. Combination approaches are under study to maximize therapeutic efficacy in patients who have progressed on standard therapies[1][3][5][7].
- Other names
- AVZO-1418AVZO1418AVZO 1418DB-1418DB1418DB 1418
02
Targets
TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on AVZO-1418 + combination agent 1 + combination agent 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVZO-1418 + combination agent 1 + combination agent 2.